Prolia (Denosumab) Cost in Massachusetts: Prices, Insurance, and Savings in 2026

Denosumab is a biologic medication marketed under two brand names for two different uses: Prolia, a 60 mg injection given once every six months for osteoporosis and certain cancer-treatment-related bone loss, and Xgeva, a 120 mg monthly injection approved for a different set of oncology indications. This article covers Prolia only. The dosing, pricing, and coverage rules for Xgeva are not the same and should not be assumed to transfer.

The core answer, with its boundaries: Prolia is FDA-approved for postmenopausal osteoporosis, bone loss from androgen- or aromatase-deprivation cancer therapy, and glucocorticoid-induced osteoporosis, given as a 60 mg subcutaneous injection every six months. Reported US list prices for a single injection have been in the roughly $1,500 range in recent years, but this figure moves and a Massachusetts pharmacy or clinic quote should be treated as the source of truth, not this page. MassHealth, commercial insurance, and Medicare Part B each cover Prolia through different benefit pathways with different patient cost-sharing, and the manufacturer's copay assistance program is available only to commercially insured patients, not to anyone enrolled in a government health plan.

What Prolia costs without insurance in Massachusetts

Denosumab has no generic or biosimilar equivalent on the US market as of this writing, so the cash price at a Massachusetts pharmacy or infusion clinic tracks close to the manufacturer's list price. Amgen's publicly stated list price for a single Prolia injection has been reported at roughly $1,500 in recent years; because list prices and pharmacy acquisition costs change periodically, a specific dollar figure should be confirmed directly with the dispensing pharmacy or clinic and with Amgen at the time a patient is scheduling treatment, not assumed from an article.

Two practical add-ons matter for uninsured patients. First, hospital-based infusion or injection sites sometimes bill a separate facility fee on top of the drug cost, which is common at academic medical centers. Second, because Prolia is a flat 60 mg dose regardless of body weight, there is no dose-based way to lower the per-injection cost the way there sometimes is with weight-based drugs.

For context, oral bisphosphonates such as alendronate are inexpensive by comparison and remain a reasonable first-line option for many patients with osteoporosis, according to endocrine society guidance on stepwise treatment selection. The choice between an oral bisphosphonate and Prolia depends on kidney function, GI tolerance, adherence history, and fracture risk, and is a decision to make with a prescriber rather than by cost alone.

Does MassHealth cover Prolia?

MassHealth (Massachusetts Medicaid) covers Prolia when prior authorization criteria are met. In general, Medicaid programs require documentation of a qualifying diagnosis and, frequently, evidence that a first-line oral bisphosphonate was tried, not tolerated, or contraindicated. The specific turnaround time for a MassHealth prior authorization request and the exact copay a given enrollee owes depend on the member's specific MassHealth plan and change periodically; these details should be confirmed directly with MassHealth or the member's MassHealth managed care organization rather than assumed.

One detail worth flagging to patients: payers sometimes classify Prolia as a medical benefit rather than a pharmacy benefit when it is administered in a physician's office, because it is injected rather than self-administered. Whether MassHealth processes a given patient's claim under the medical benefit or the pharmacy benefit can change the prior authorization pathway and the cost-sharing rules that apply, so this is worth confirming with the specific MassHealth plan before treatment.

How commercial insurance in Massachusetts typically handles Prolia

Most major commercial insurers operating in Massachusetts cover Prolia, generally with prior authorization and often with a step-therapy requirement showing a prior trial of an oral bisphosphonate. Beyond that general pattern, cost-sharing structure varies by plan design: some plans place specialty biologics on a coinsurance tier (a percentage of the drug's cost), others use a flat specialty copay, and high-deductible plans may require the patient to pay the full negotiated price until the deductible is met. Because plan design differs by employer and by year, a patient's actual out-of-pocket cost cannot be estimated accurately without checking the specific plan's summary of benefits or calling member services.

Employer-sponsored plans governed by federal ERISA rules can have different formulary and appeal processes than Massachusetts state-regulated individual or small-group plans, which must meet the state's essential health benefit benchmark for osteoporosis treatment coverage. Formulary placement of a specific drug like Prolia, however, is generally left to the insurer's discretion within that framework.

The Amgen copay savings program

Amgen has historically offered a copay assistance program for commercially insured Prolia patients that reduces out-of-pocket cost, sometimes to $0, up to an annual maximum. Eligibility for manufacturer copay cards is generally limited to patients with commercial (non-government) insurance; enrollees in Medicare, Medicaid, TRICARE, or VA benefits are typically excluded by federal Anti-Kickback Statute rules that prohibit combining manufacturer copay assistance with federal health program billing. The specific dollar cap on Amgen's current program, and whether it is billed at the point of sale or requires a separate claim when Prolia is administered as a medical benefit in a clinic, should be verified directly on Amgen's program page or by calling the number listed there before assuming a specific savings amount, since these terms are adjusted periodically.

Medicare and MassHealth enrollees who need financial help should instead ask about the Amgen Safety Net Foundation, a separate income-based patient assistance program intended for patients not eligible for manufacturer copay cards.

Compounded denosumab: a real but legally narrower option than it may sound

Some compounding pharmacies advertise or offer compounded denosumab at a lower price than the branded product. This needs more scrutiny than compounded small-molecule drugs get. Denosumab is a biologic licensed under a Biologics License Application (BLA), not a conventional chemical drug, and the FDA has published specific guidance distinguishing legitimate patient-specific compounding from activities that amount to unauthorized manufacturing or copying of an approved biologic, and general FDA guidance distinguishes legitimate patient-specific compounding from activities that amount to unauthorized manufacturing or copying of an approved biologic. Because Prolia is protein-based and requires sterile, cold-chain handling, a compounded version is not automatically equivalent in purity, potency, or immunogenicity to the FDA-approved product, and it is not FDA-approved itself.

In Massachusetts, sterile compounding is regulated by the Board of Registration in Pharmacy under USP <797> and USP <800> standards, and a pharmacy must hold the appropriate sterile compounding license and a patient-specific prescription to compound legally under Section 503A of the FD&C Act. Whether a given pharmacy's compounded denosumab product is operating within that legal boundary, versus effectively manufacturing a copy of a commercially available biologic (which 503A does not permit when a therapeutically equivalent approved product is available), is a case-by-case legal and quality question. A patient considering a compounded denosumab product should ask the pharmacy directly what source material and process are used, confirm the pharmacy's current license status with the Board of Registration in Pharmacy, and discuss the decision with the prescribing clinician rather than treating price alone as the deciding factor.

Medicare coverage for Prolia in Massachusetts

Medicare Part B covers Prolia when it is administered in a provider's office or outpatient setting, which is the normal route of administration. Under standard Part B cost-sharing, the patient owes the annual Part B deductible plus 20% coinsurance on the Medicare-approved amount; the exact deductible amount changes annually and should be confirmed against the current-year CMS figure rather than assumed from a prior year's number. Medigap (Medicare Supplement) plans can offset some or all of that coinsurance depending on the plan type, and Massachusetts uses its own standardized Medigap plan structure rather than the federal lettered-plan system used in most states, so a Massachusetts enrollee should check plan-specific documents.

Medicare Advantage plans operating in Massachusetts are required by CMS to cover at least what Original Medicare covers, but they can apply their own prior authorization and cost-sharing rules within that requirement, so a specific Advantage plan's Prolia copay or coinsurance should be confirmed with that plan directly.

As noted above, manufacturer copay cards generally cannot be used by Medicare beneficiaries because of federal Anti-Kickback Statute restrictions on combining private copay assistance with federal program billing; Medicare patients needing help with cost should ask about the Amgen Safety Net Foundation or other independent, disease-based charitable copay foundations that are structured to be compliant with federal program rules.

Telehealth prescribing in Massachusetts

Massachusetts permits telehealth evaluation and prescribing, including for medications like Prolia, by a clinician holding an active Massachusetts medical license, following flexibilities that became permanent under state law after the COVID-19 public health emergency. The Board of Registration in Medicine oversees physician licensure and practice standards in the state. In practice, a telehealth visit can be used to review bone density results, fracture history, and treatment options, and to issue a prescription, but the injection itself must still be given in person, either at the prescriber's office, an infusion center, or through a home health visit, since Prolia is not self-injected.

This model can reduce the burden of specialist access for patients in parts of the state farther from a major medical center, provided the in-person injection step is scheduled reliably.

What is established versus what needs verification (evidence boundary)

Established from FDA labeling and clinical guideline sources: Prolia is FDA-approved for postmenopausal osteoporosis, bone loss associated with certain hormone-ablation cancer therapies, and glucocorticoid-induced osteoporosis, dosed as a 60 mg subcutaneous injection every six months. Discontinuing denosumab is associated with a rebound increase in bone turnover and has been linked in the literature to increased vertebral fracture risk after stopping, which is why clinicians typically plan a transition therapy (often a bisphosphonate) around discontinuation; a patient should not stop Prolia without discussing a transition plan with their prescriber.

Plausible but requiring current verification: the specific dollar figures in this article for list price, MassHealth copay amounts, PA turnaround time, savings card annual caps, and the Medicare Part B deductible are all volatile and should be confirmed against current MassHealth, Amgen, and CMS sources at the time a patient is making a decision, not assumed from this page.

Not established here: this article does not have a verified primary citation for the exact magnitude of fracture-risk reduction reported in denosumab's pivotal trial literature. Readers who need the precise trial-reported effect sizes should consult the FDA-approved prescribing information and the peer-reviewed trial publication directly rather than relying on a secondhand number.

Verification checklist: what is stable versus what changes

Use this before relying on any specific number in this article or elsewhere online.

Stable facts that do not change month to month (verify once, against a primary source):

• FDA-approved indications and dosing schedule for Prolia, confirm against the current FDA-approved label
• Whether denosumab is a biologic (BLA product) versus a conventional small-molecule drug, which affects compounding legality
• Massachusetts pharmacy licensing and sterile compounding requirements, via the Board of Registration in Pharmacy
• Massachusetts telehealth prescribing authority, via the Board of Registration in Medicine
• The general rule that manufacturer copay cards cannot be combined with Medicare or Medicaid (federal Anti-Kickback Statute)

Date-sensitive facts that must be reverified before a patient relies on them:

• Current Amgen list price and Massachusetts retail/clinic cash price for a Prolia injection
• Current Amgen Prolia savings card terms, annual cap, and enrollment process
• MassHealth prior authorization criteria, processing time, and member cost-share for the patient's specific plan
• The specific commercial insurer's formulary tier, step-therapy rule, and coinsurance or copay for Prolia
• The current-year Medicare Part B deductible and coinsurance amount
• Whether a specific Medicare Advantage plan requires prior authorization and what it charges
• Whether a specific 503A pharmacy currently holds an active sterile compounding license and what its compounded denosumab product actually contains

Who to ask for each: MassHealth member services or the member's MassHealth managed care organization for Medicaid questions; the commercial insurer's member services line for plan-specific cost-sharing; Amgen's program line for savings card terms; CMS.gov or the specific Medicare Advantage plan for Medicare cost questions; the Massachusetts Board of Registration in Pharmacy for a compounding pharmacy's license status.

Other assistance pathways worth asking about

Independent, disease-focused charitable copay foundations sometimes offer assistance for osteoporosis medications separate from the manufacturer's own program, and these can be usable by Medicare patients when the foundation is structured independently of Amgen. Community health centers and hospitals that participate in the federal 340B Drug Pricing Program may have access to discounted acquisition costs, though those savings are not always passed directly to the patient. Massachusetts's Health Safety Net program provides certain coverage for lower-income residents not eligible for MassHealth, and coverage of a specific drug like Prolia under that program should be confirmed with the treating facility. General discount cards such as GoodRx or SingleCare sometimes list Prolia, but discounts on specialty biologics are typically modest compared with what those cards can do for common generic drugs, and any specific discounted price quoted by such a service should be checked at the actual pharmacy before assuming it will apply.